{
    "url_original": "https://www.wsj.com/articles/astrazeneca-vaccine-effective-against-u-k-covid-19-variant-in-study-11612530912?mod=business_lead_pos5",
    "url": "astrazeneca-vaccine-effective-against-u-k-covid-19-variant-in-study-11612530912",
    "title": "AstraZeneca Vaccine Effective Against U.K. Covid-19 Variant in Trial",
    "sub_head": "Study finds the vaccine’s efficacy against the U.K. variant is 75%",
    "category_1": "Business",
    "image_1_url": "https://images.wsj.net/im-295515?width=620&size=1.5",
    "image_1": "im-295515.jpg",
    "time": "2021-02-05 08:15:00",
    "body": "LONDON—The vaccine jointly developed by the University of Oxford and AstraZeneca PLC worked against a highly transmissible variant of the coronavirus first spotted in the U.K. in a clinical trial, the university said Friday.<br />The vaccine’s effectiveness against the U.K. variant was estimated to be 75%, compared with 84% for older variants.<br />Write to Jason Douglas at jason.douglas@wsj.com"
}